Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.

Blood cancer journal - 31 Jul 2021

Jia Ruochen, Kutzner Leon, Koren Anna, Runggatscher Kathrin, Májek Peter, Müller André C, Schuster Michael, Bock Christoph, Loizou Joanna I, Kubicek Stefan, Kralovics Robert

Abstract excerpt

Mutations of calreticulin (CALR) are the second most prevalent driver mutations in essential thrombocythemia and primary myelofibrosis. To identify potential targeted therapies for CALR mutated myeloproliferative neoplasms, we searched for small molecules that selectively inhibit the growth of CALR mutated cells using high-throughput drug screening. We investigated 89 172 compounds using isogenic cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 1

Share to Drug Discovery

Share to Drug Evaluation, Preclinical

Share to High-Throughput Screening Assays

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 34333533
DOI: 10.1038/s41408-021-00531-2
PMCID: PMC8325683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells.PMID 34333533Read ↗

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.Semantic proximity Read ↗

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.Semantic proximity Read ↗

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Semantic proximity Read ↗

Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis.Semantic proximity Read ↗

The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.Semantic proximity Read ↗

Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stressSemantic proximity Read ↗

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor.Semantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signalingSemantic proximity Read ↗

Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.Semantic proximity Read ↗

CALR mutation screening in pediatric primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.